Key facts
- This page summarizes Dexcel Pharma Technologies Ltd.'s Form 4 filing for Protalix BioTherapeutics, Inc. (PLX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2021, 17:40.
Dexcel Pharma Technologies Ltd. - 02 Jun 2021 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PLX
- Reported as of
- 02 Jun 2021
- Net transaction value
- -$2,088,857
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2021, 17:40:30 UTC
- Next SEC filing
- 01 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Dexcel Pharma Technologies Ltd. filed Form 4 for Protalix BioTherapeutics, Inc. (PLX) on 03 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$2,088,857.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLX
transaction
Common Stock
Sale
- Transaction value
- $156,553
- Shares
- -61,211
- Change %
- -1.3%
- Price
- $2.56
- Shares after
- 4,494,820
- Date
- 02 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F4
PLX
transaction
Common Stock
Sale
- Transaction value
- $1,932,304
- Shares
- -857,506
- Change %
- -19%
- Price
- $2.25
- Shares after
- 3,637,314
- Date
- 03 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Dexcel Pharma Technologies Ltd. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
Dexcel Pharma Technologies Ltd ("DPT") and Dan Oren, DPT's Executive Chairman, are filing this Form 4 because they have beneficial ownership over common stock of Protalix BioTherapeutics, Inc. The shares are directly owned by DPT. Mr. Oren is ultimately the sole shareholder of DPT.
Footnote F2
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.530 to $2.565, inclusive.
Footnote F3
The price reported in Column 4 is the weighted average price. The common shares were sold in multiple transactions at prices ranging from $2.200 to $2.450, inclusive.
Footnote F4
The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.